Article
Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients.
Department of Internal Medicine, University of Genoa, Viale Benedetto XV, n6, I-16132 Genoa, Italy.
Cerebrovascular Diseases (impact factor:
2.72).
02/2001;
11(2):113-8.
DOI:47622
pp.113-8
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Vasopressin in vascular regulation and water homeostasis in the brain.
[show abstract] [hide abstract]
ABSTRACT: It is well known that vasopressin participates in the regulation of the cardiovascular system, water electrolyte balance and many functions of the central nervous system. Receptors for vasopressin are widely distributed throughout the brain. They are present in neurons, in astrocytes and their perivascular processes, in endothelial and smooth muscle cells of blood vessels and in choroid plexus. Such a location suggests that vasopressin may participate in the regulation of vascular resistance in cerebral circulation and water homeostasis in the brain. Present review of the data published on this subject suggests that endogenous vasopressin is involved in brain pathology rather than in physiological regulations. Numerous studies have shown increased release of vasopressin and expression of vasopressin receptors in the brain following ischemia, trauma or subarachnoid hemorrhage in patients and in animal models of these diseases. Moreover, it has been demonstrated that antagonists of vasopressin V(1a) receptors are able to alleviate brain edema and spastic changes in blood vessels after subarachnoid hemorrhage. Vasopressin is also implicated in brain edema and in impairment of cerebral vasculature in hypo-osmotic states. The discussed results suggest that vasopressin V(1a) receptors antagonists may be a useful tool for the treatment of some states associated with cerebrovascular pathology.Journal of physiology and pharmacology: an official journal of the Polish Physiological Society 01/2009; 59 Suppl 8:109-16. · 2.27 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
24 patients
24-hour period
24-hour plasma AVP levels
Arginine vasopressin
AVP plasma levels
cerebral ischemia warrants
cerebral vasospasm
control subjects
Data available
increased AVP secretion
ischemic brain edema
ischemic stroke
mean 24-hour plasma AVP levels
mean size
neurologic deficit
neuronal cell damage
plasma AVP levels
severe neurologic deficit
stroke patients
unprecedented ischemic cerebral infarction